Existence of the Diffusion-Perfusion Mismatch within 24 Hours after Onset of Acute Stroke: Dependence on Proximal Arterial Occlusion

被引:76
作者
Copen, William A. [1 ,3 ]
Gharai, Leila Rezai [1 ]
Barak, Elizabeth R. [1 ]
Schwamm, Lee H. [2 ,3 ]
Wu, Ona [1 ,3 ]
Kamalian, Shahmir [1 ]
Gonzalez, R. Gilberto [1 ,3 ]
Schaefer, Pamela W. [1 ,3 ]
机构
[1] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA
[3] Harvard Univ, Sch Med, Boston, MA USA
关键词
ACUTE ISCHEMIC-STROKE; TISSUE-PLASMINOGEN-ACTIVATOR; POSITRON-EMISSION-TOMOGRAPHY; FOCAL CEREBRAL-ISCHEMIA; THROMBOLYTIC THERAPY; PERIINFARCT DEPOLARIZATIONS; INTRAARTERIAL THROMBOLYSIS; INTRAVENOUS THROMBOLYSIS; CONTROLLED-TRIAL; BLOOD-VOLUME;
D O I
10.1148/radiol.2503080811
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To assess the existence of a mismatch between lesions on diffusion-weighted (DW) and perfusion-weighted (PW) magnetic resonance (MR) images obtained within 24 hours after onset of acute stroke and to use mismatch data and angiographic evidence of proximal arterial occlusion (PAO) to investigate whether the existence of the mismatch depends on the existence of PAO. Materials and Methods: In this institutional review board-approved, HIPAA-compliant study, 109 retrospectively identified patients had undergone DW and PW imaging within 24 hours of stroke onset. Relative mismatch was computed as the difference between lesion volumes on mean transit time maps and DW images, divided by DW lesion volume. Computed tomographic (CT) angiography or MR angiography distinguished patients with PAO (n = 68) from those with no PAO (NPAO; n = 41). Eligibility for hypothetical thrombolysis was assessed with two different criteria: (a) one derived from the successful Desmoteplase in Acute Ischemic Stroke Trial (DIAS) and Dose Escalation of Desmoteplase for Acute Ischemic Stroke Trial (DEDAS), and (b) another requiring 160% mismatch. Results: Of the 109 patients, 77 (71%) satisfied the DIAS-DEDAS eligibility criteria, and 61 (56%) satisfied the 160% criterion. The NPAO patients demonstrated decreasing eligibility with increasing time after onset by using DIAS-DEDAS criteria (P = .015) and showed a similar trend with the 160% criterion (P = .078). The NPAO patients were less likely to be eligible after 9 hours than before 9 hours (17% for > 9 hours vs 72% for < 9 hours with DIAS-DEDAS criteria, P = .002; and 8% for > 9 hours vs 45% for < 9 hours with 160% criterion, P = .033). However, PAO patients demonstrated a trend toward increasing eligibility with the DIAS-DEDAS criteria (P = .099) and no significant difference for after 9 hours versus before 9 hours (84% for > 9 hours vs 78% for < 9 hours with DIAS-DEDAS criteria, P = .742; and 68% for > 9 hours vs 69% for < 9 hours with 160% criterion, P > .999). Conclusion: Persistence of mismatch after 9 hours is common and occurs most often in patients with PAO. (c) RSNA, 2009
引用
收藏
页码:878 / 886
页数:9
相关论文
共 43 条
  • [1] Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility
    Barber, PA
    Zhang, J
    Demchuk, AM
    Hill, MD
    Buchan, AM
    [J]. NEUROLOGY, 2001, 56 (08) : 1015 - 1020
  • [2] Inflammatory mediators and stroke: New opportunities for novel therapeutics
    Barone, FC
    Feuerstein, GZ
    [J]. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 1999, 19 (08) : 819 - 834
  • [4] Potassium-induced cortical spreading depressions during focal cerebral ischemia in rats: Contribution to lesion growth assessed by diffusion-weighted NMR and biochemical imaging
    Busch, E
    Gyngell, ML
    Eis, M
    HoehnBerlage, M
    Hossmann, KA
    [J]. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 1996, 16 (06) : 1090 - 1099
  • [5] Reactive oxygen radicals in signaling and damage in the ischemic brain
    Chan, PH
    [J]. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2001, 21 (01) : 2 - 14
  • [6] Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset - The ATLANTIS study: A randomized controlled trial
    Clark, WM
    Wissman, S
    Albers, GW
    Jhamandas, JH
    Madden, KP
    Hamilton, S
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21): : 2019 - 2026
  • [7] Reasons for exclusion from thrombolytic therapy following acute ischemic stroke
    Cocho, D
    Belvís, R
    Martí-Fàbregas, J
    Molina-Porcel, L
    Díaz-Manera, J
    Aleu, A
    Pagonabarraga, J
    García-Bargo, D
    Mauri, A
    Martí-Vilalta, JL
    [J]. NEUROLOGY, 2005, 64 (04) : 719 - 720
  • [8] Pathophysiological topography of acute ischemia by combined diffusion-weighted and perfusion MRI
    Darby, DG
    Barber, PA
    Gerraty, RP
    Desmond, PM
    Yang, Q
    Parsons, M
    Li, T
    Tress, BM
    Davis, SM
    [J]. STROKE, 1999, 30 (10) : 2043 - 2052
  • [9] RECOMBINANT TISSUE PLASMINOGEN-ACTIVATOR IN ACUTE THROMBOTIC AND EMBOLIC STROKE
    DELZOPPO, GJ
    POECK, K
    PESSIN, MS
    WOLPERT, SM
    FURLAN, AJ
    FERBERT, A
    ALBERTS, MJ
    ZIVIN, JA
    WECHSLER, L
    BUSSE, O
    GREENLEE, R
    BRASS, L
    MOHR, JP
    FELDMANN, E
    HACKE, W
    KASE, CS
    BILLER, J
    GRESS, D
    OTIS, SM
    [J]. ANNALS OF NEUROLOGY, 1992, 32 (01) : 78 - 86
  • [10] Combined intravenous and intra-arterial recombinant tissue plasminogen activator in acute ischemic stroke
    Ernst, R
    Pancioli, A
    Tomsick, T
    Kissela, B
    Woo, D
    Kanter, D
    Jauch, E
    Carrozzella, J
    Spilker, J
    Broderick, J
    [J]. STROKE, 2000, 31 (11) : 2552 - 2557